Upload
lydia-dawson
View
216
Download
0
Embed Size (px)
Citation preview
NOTCH-1
PR
E- T
- CE
L L AC
UT
E L
YM
PH
OB
L AS
TI C
LE
UK
EM
I AS
NOTCH WAS FIRST IDENTIFIED IN THE FRUIT FLY DROSOPHILA
NOTCH SIGNALING REGULATES MULTIPLE ASPECTS OF INVERTEBRATE AND VERTEBRATE
DEVELOPMENT.
WHAT HAPPENS TO A MOUSE THAT LACKS NOTCH 1?
NOTCH IS REQUIRED FOR T-CELL PROGENITORS OF THE AB LINEAGE TO
PROGRESS PAST THE DN3 B SELECTION CHECKPOINT FOR T-CELL DEVELOPMENT
NOTCH ENCODES A CELL SURFACE RECEPTORWITH A TRANSMEMBRANE-BOUND LIGAND
UPON LIGAND BINDING, NOTCH IS PROTEOLYTICALLY CLEAVED AND THE
CYTOPLASMIC FRAGMENTACTS AS A TRANSCRIPTION FACTOR
NOTCH1 GENE IN GENOMIC LOCATION
T- ACUTE LYMPHOBLASTIC LEUKEMIA IS AN AGGRESSIVE CANCER THAT TYPICALLY AFFECTS
CHILDREN AND ADOLESCENTS
Subtype Frequency
Early Pre-B cell 60%- 65%
Pre-B cell 20%- 25%
Mature B cell 2%- 3%
T cell 15%- 18%
CHROMOSOMAL TRANSLOCATION LEADING TO T-ALL
THE T(7;9)(Q34;Q34.3) TRANSLOCATION, WHICH OCCURS IN ~1% OF T-ALL, LEADS TO THE CONSTITUTIVE EXPRESSION OF
ACTIVE NOTCH1
NOTCH1 MUTATIONS HAVE BEEN REPORTED TO OCCUR IN 10 TO 15% OF
HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCC)
CURRENT TREATMENT OF T-ALL CONSISTS OF CHEMOTHERAPY TO
ACHIEVE REMISSION AND CENTRAL NERVOUS SYSTEM (CNS) PROPHYLAXIS TO PREVENT T-ALL FROM SPREADING TO
THE BRAIN OR SPINAL CORD
IDENTIFICATION OF GENETIC ABERRATIONS, SUCH AS NOTCH1, IS IMPORTANT IN AN ATTEMPT TO DESIGN NOVEL FORMS OF
TARGETED THERAPIES.
ACUTE LYMPHOBLASTIC LEUKEMIAS ARE RESPONSIBLE FOR ABOUT 1,400 DEATHS A YEAR IN THE U.S., AND IT CAN PROGRESS QUICKLY IF
UNTREATED. HOWEVER, ALL IS ONE OF THE MOST CURABLE CANCERS AND SURVIVAL RATES ARE
NOW AT AN ALL-TIME HIGH.• Today, more
than 95% of children with ALL attain remission.
• 60 - 80% of adults with ALL can expect to achieve full remission with standard treatments, and 35 - 40% survive beyond 2 years with aggressive treatments
A NOTABLE DIFFERENCE OF RELAPSE-FREE SURVIVAL EXISTS BETWEEN PATIENTS POSITIVE
AND NEGATIVE FOR NOTCH1 MUTATION
SUMMARY
• Activation of Notch is a frequent event in T-ALL
• Notch mutations are found in >50% of pediatric and adult T-ALLs
• Inhibition of gamma-secretase activity results in inhibition of leukemia cell Notch signaling.
• Use of gamma-secretase inhibitors is a rational approach to the therapy of T-ALL
SOURCESAcute Lymphocytic Leukemia. (n.d.). Retrieved March 2015.
Chiaretti S, Foà R. T-cell acute lymphoblastic leukemia. Haematologica. 2009;94(2):160-162. doi:10.3324/haematol.2008.004150.
Grabher, C., von Boehmer, H., & Look, A. T. (2006). Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nature Reviews Cancer, 6(5), 347-359.
How is childhood leukemia classified? (n.d.). Retrieved March 2015.
Radtke, F., & Raj, K. (2003). The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nature Reviews Cancer, 3(10), 756-767.
Sun W, Gaykalova DA, Ochs MF, et al. Activation of the NOTCH pathway in Head and Neck Cancer. Cancer research. 2014;74(4):1091-1104. doi:10.1158/0008-5472.CAN-13-1259.
Swiatek, P. J., Lindsell, C. E., Del Amo, F. F., Weinmaster, G., & Gridley, T. (1994). Notch1 is essential for postimplantation development in mice. Genes & development, 8(6), 707-719.
Weinberg, Robert A. The Biology of Cancer. New York: Garland Science, 2014. Print.
Zhu, Y. M., Zhao, W. L., Fu, J. F., Shi, J. Y., Pan, Q., Hu, J., ... & Chen, S. J. (2006). NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clinical Cancer Research, 12(10), 3043-3049.